DIG
TRVI icon

Dauntless Investment Group’s Trevi Therapeutics TRVI Stock Holding History

Dauntless Investment Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19 Buy
+1
New +$15 ﹤0.01% 71
2025
Q3 		– Sell
-29,000
Closed -$159K – 101
2025
Q2 		$159K Buy
+29,000
New +$180K 0.28% 46

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Dauntless Investment Group's TRVI Position: Q2 2026 in Review

Dauntless Investment Group opened a new position in Trevi Therapeutics (TRVI) in Q2 2026: 1 share worth $19. The stake represents ﹤0.01% of the portfolio and ranks #71 among its holdings. This is a return to the name: Dauntless Investment Group previously reported a position in TRVI as recently as Q2 2025.

Dauntless Investment Group first reported a position in TRVI in Q2 2025 and has held it in 2 quarters since. The position peaked at $159K in Q2 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Dauntless Investment Group held 1 share of Trevi Therapeutics worth $19 as of Q2 2026.
  • Trevi Therapeutics was a new Dauntless Investment Group position in Q2 2026.
  • Trevi Therapeutics made up ﹤0.01% of Dauntless Investment Group's portfolio in Q2 2026, its #71 holding.
  • Dauntless Investment Group first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Dauntless Investment Group's Trevi Therapeutics position peaked at $159K in Q2 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.